<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648100</url>
  </required_header>
  <id_info>
    <org_study_id>NI 13021</org_study_id>
    <nct_id>NCT02648100</nct_id>
  </id_info>
  <brief_title>Basal Like Bladder Cancer : Signature and Therapeutic</brief_title>
  <acronym>DIATRIBBE</acronym>
  <official_title>Identification and Treatments of Basal Like Bladder Cancer (Study on Human Tumor Samples and Animal Models)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paris 12 Val de Marne University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Muscle invasive (MIBC) and/or metastatic bladder cancer is associated with poor prognosis and&#xD;
      no target therapies for this pathology are currently validated. By 40 gene expression&#xD;
      signature realized on frozen samples, we have previously identified an aggressive sub-class&#xD;
      of MIBC, called basal. This sub-class (20% of MIBC) showed strong EGFR dependence in vitro&#xD;
      and in vivo (Rebouissou et al. Science Translational Medicine 2014). This observation&#xD;
      suggests a possible response to EGFR targeted therapy in patients of this subgroup. Our aim&#xD;
      is to establish a standard diagnostic tool to differentiate the basal subtype of bladder&#xD;
      cancer and evaluate the effect of anti-EGFR therapy, by analyzing previous clinical trial&#xD;
      (GETUG19) and preclinical models, which compare the classical chemotherapy to anti-EGFR&#xD;
      associated chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is:&#xD;
&#xD;
        1. To validate a diagnostic test for formalin-fixed paraffin-embedded (FFPE) samples by&#xD;
           Nanostring technology, using the 40 genes signature as reference. First, we will compare&#xD;
           frozen and FFPE tissues (n=120), to establish a transcriptional signature in FFPE&#xD;
           samples. Secondly, to further characterize basal subtype of bladder cancer, we will&#xD;
           study the mutational and gain/loss landscape and immunohistochemistry markers in a new&#xD;
           series of tumors after classifying them by our gene signature (n=510). These&#xD;
           characteristics will be included in a new signature by defining the optimal prediction&#xD;
           discrimination AIC et Net Reclassification Index.&#xD;
&#xD;
        2. To assess the prognosis after cisplatine treatment in 510 patients treated by cystectomy&#xD;
           with or without adjuvant chemotherapy (pT2/pT3/pT4, N0 or N+) and in another&#xD;
           multicentric series of 188 patients treated by cystectomy and adjuvant chemotherapy&#xD;
           (pT3/pT4 et/ou N+). Uni and multi variant analysis will be realized by adjusted Cox&#xD;
           model, and the added value of basal subtype as compared to standard prognostic factors&#xD;
           will be evaluated. The propensity score will be realized to assess the association of&#xD;
           basal subtype and response to chemotherapy. The anti-EGFR response will be analyzed in&#xD;
           the clinical trial GETUG19 which uses Panitumumab in patients with metastatic urothelial&#xD;
           carcinomas (n=93)&#xD;
&#xD;
        3. To study the treatment response in preclinical models. We characterized previously&#xD;
           preclinical murine models derived from xenografts of MIBC (n=14 and new xenografts will&#xD;
           be added). We will study the effect of anti-EGFR alone or in combination with&#xD;
           chemotherapy in basal and non basal subtypes of xenografts.&#xD;
&#xD;
      By this study we will be able to better characterize the basal subtype of bladder cancer and&#xD;
      confirm its aggressive behaviour as compared to other subtypes of MIBC. These results will&#xD;
      further help to establish new clinical trials which include anti-EGFR in patients of basal&#xD;
      subtype.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">911</enrollment>
  <condition>Muscle Invasive Bladder Cancer</condition>
  <condition>Molecular Taxonomy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>120 patients from Carte d'Identité des Tumeurs (CIT), Henri Mondor and Foch hospitals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>510 cystectomy patients operated between 2005 and 2010 in Henri Mondor and Foch hospitals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <description>188 patients treated by cystectomy and adjuvant chemotherapy for locally advanced bladder cancer from a national multicentric study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <description>93 patients from the clinical trial GETUG 19 (UNICANCER)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biomarker study</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue : frozen (n=120), FFPE (n=911)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Bladder Cancer from 4 cohorts&#xD;
&#xD;
          -  2 observational cohorts of patients with muscle invasive bladder cancer (all stages)&#xD;
             from two Henri Mondor (Créteil) and Foch (Suresnes) hospitals&#xD;
&#xD;
          -  1 multicentric observational cohort of patients with locally advanced muscle invasive&#xD;
             bladder cancer trated by adjuvantchemotherapy after cystectomy&#xD;
&#xD;
          -  1 clinical trial GETUG 19 (MVAC + panitumumab)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Muscle invasive bladder cancer Treatment by cystectomy Adjuvant chemotherapy for 3rd cohort&#xD;
        Clinical trial GETUG 19 for 4th cohort&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        FFPE material not available Follow-up data not available&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves ALLORY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yves ALLORY, MD, PhD</last_name>
    <phone>(0)1 49 81 27 29</phone>
    <phone_ext>+33</phone_ext>
    <email>yves.allory@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François RADVANYI, PhD</last_name>
    <phone>(0)1 42 34 63 39</phone>
    <phone_ext>+33</phone_ext>
    <email>francois.radvanyi@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscle invasive bladder cancer</keyword>
  <keyword>Basal subtype</keyword>
  <keyword>Anti-EGFR treatment</keyword>
  <keyword>Nanostring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

